Difference between revisions of "Vandetanib (Caprelsa)"
m |
|||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | |||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| + | *[[Thyroid cancer]] | ||
| + | **[[Differentiated thyroid cancer]] | ||
| + | **[[Medullary thyroid cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 16: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 4/6/2011: Initial FDA approval for the treatment of symptomatic or progressive [[ | + | * 4/6/2011: Initial FDA approval for the treatment of symptomatic or progressive [[medullary thyroid cancer]] in patients with unresectable locally advanced or metastatic disease. ''(Based on ZETA)'' |
==Also known as== | ==Also known as== | ||
| Line 27: | Line 29: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:EGFR inhibitors]] | [[Category:EGFR inhibitors]] | ||
| Line 37: | Line 38: | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| − | [[Category: | + | [[Category:Differentiated thyroid cancer medications]] |
| + | [[Category:Medullary thyroid cancer medications]] | ||
[[Category:REMS program]] | [[Category:REMS program]] | ||
[[Category:FDA approved in 2011]] | [[Category:FDA approved in 2011]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
Revision as of 18:17, 21 September 2021
General information
Class/mechanism: from the NCI Drug Dictionary: "An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis." Also a tyrosine kinase inhibitor of RET (rearranged during transfection), BRK (breast tumor kinase/protein tyrosine kinase 6), TIE2, EPH, Src. Inhibits angiogenesis, endothelial cell migration, and tumor growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Vandetanib (Caprelsa) package insert PDF pages 6-8[5]
- Vandetanib (Caprelsa) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 4/6/2011: Initial FDA approval for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. (Based on ZETA)
Also known as
- Code names: AZD6474, ZD6474
- Brand names: Caprelsa, Zactima
References
- ↑ 1.0 1.1 Vandetanib (Caprelsa) package insert
- ↑ Vandetanib (Caprelsa) package insert (locally hosted backup)
- ↑ Caprelsa manufacturer's website
- ↑ Caprelsa Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Vandetanib (Caprelsa) package insert PDF pages 6-8
- ↑ Vandetanib (Caprelsa) patient drug information (UpToDate)